PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50120C00001Antibiotic for treatment of a biothreat — Paratek Pharmaceuticals, Inc

Paratek Pharmaceuticals, Inc holds $40.7M across 2 federal awards, concentrated at Department of Health and Human Services (HHS). Competition previously drew 4 offers. Set-aside status: NONE. Recompete timing centers on the Dec 17, 2029 PoP end — agencies typically plan 12–18 months ahead.

Barda - Aspr / Daappo / Barda Dcma

Awarding office

Paratek Pharmaceuticals, Inc

Recipient

Dec 17, 2029

PoP end

$108.7M

Obligated

541714

NAICS

6505

PSC

NONE

Set-aside

4 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Paratek Pharmaceuticals, Inc — $90

Contract facts

NONE

Contract number75A50120C00001

AgencyBarda - Aspr / Daappo / Barda Dcma

Awarding officeBarda - Aspr / Daappo / Barda Dcma

IncumbentParatek Pharmaceuticals, Inc

UEID5KEFN62CJ97

NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSC6505

Place of performanceBOSTON, MA

Related solicitation19-100-SOL-00011

PoP end (current)Dec 17, 2029

Obligated$108.7M

ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION is a federal NONE award for Barda - Aspr / Daappo / Barda Dcma held by Paratek Pharmaceuticals, Inc. Estimated value $265.3M ($108.7M obligated). Current period of performance ends Dec 17, 2029. Last award drew 4 bidders. Place of performance: BOSTON, MA. Related solicitation 19-100-SOL-00011.

ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION

Recompete timing

Public

● Expiring in 1202 days

Current PoP ends Dec 17, 2029 (1202 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Jun 17, 2028.

Incumbent footprint

Public record

Paratek Pharmaceuticals, Inc — $40.7M obligated across 2 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$40.7M · 100% of firm total

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50120C00001?

75A50120C00001 (Antibiotic for treatment of a biothreat) is a Barda - Aspr / Daappo / Barda Dcma award with an estimated value of $265.3M, currently held by Paratek Pharmaceuticals, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50120C00001?

Barda - Aspr / Daappo / Barda Dcma awarded 75A50120C00001 to Paratek Pharmaceuticals, Inc.

Who is the incumbent on 75A50120C00001?

Paratek Pharmaceuticals, Inc is the incumbent with $40.7M across 2 related awards in SCOUT’s public footprint. The current period of performance ends Dec 17, 2029.

When does Paratek Pharmaceuticals, Inc’s 75A50120C00001 come up for recompete?

SCOUT tracks a period-of-performance end of Dec 17, 2029. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on 75A50120C00001 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action Mar 2, 2026